Eli Lilly and Novo Nordisk require 340B claims data within 45 days
Issue
Eli Lilly (from February 1) and Novo Nordisk (from April 1, 2026) now require 340B covered entities, including health centers, to submit claims-level data for each dispense within 45 days or risk losing 340B pricing. AHA urged HRSA to stop both policies, and HRSA has not acted.
Centers with many GLP-1 and insulin patients face the most risk.
Key points
- Health centers using Novo Nordisk or Eli Lilly drugs under 340B must send claims data within 45 days of each dispense. Pharmacy directors should set up tracking now.
- Missing the deadline risks losing 340B pricing on GLP-1s and insulin, a big hit for centers with many diabetes patients.
Sources for this story
AHAPart of
- 340B drug pricing
Manufacturer restrictions and data demands
Sources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
The newsletter is paused right now. Sign up and you will get it when it starts again.
Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
FQHC Talent. (2026, April 1). Eli Lilly and Novo Nordisk require 340B claims data within 45 days. Source: AHA. Retrieved November 22, 2026, from https://www.fqhctalent.com/intel/eli-lilly-novo-340b-claims-data-mandate-active-2026